Histone methyltransferase: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
== Relevance == | == Relevance == | ||
Inhibitors of the histone-lysine N-methyltransferase SMYD2 which represses the tumor-suppressing activities of p53 are studied as cancer therapy | Inhibitors of the histone-lysine N-methyltransferase SMYD2 which represses the tumor-suppressing activities of p53 are studied as cancer therapy drugs<ref>PMID:21782458</ref>. | ||
== Disease == | == Disease == | ||
| Line 64: | Line 64: | ||
*Histone-lysine N-methyltransferase binary complexes | *Histone-lysine N-methyltransferase binary complexes | ||
**[[2kkf]] – hKHMT Hrx CxxC domain + | **[[2kkf]] – hKHMT Hrx CxxC domain + DNA – NMR<br /> | ||
**[[4nw3]] – hKHMT Mll CxxC domain + DNA <br /> | **[[4nw3]] – hKHMT Mll CxxC domain + DNA <br /> | ||
**[[4pzi]] – hKHMT CxxC domain + DNA <br /> | **[[4pzi]] – hKHMT CxxC domain + DNA <br /> | ||
**[[3q0b]], [[3q0c]], [[3q0d]], [[3q0f]] – hKHMT SRA domain + | **[[3q0b]], [[3q0c]], [[3q0d]], [[3q0f]] – hKHMT SRA domain + DNA <br /> | ||
**[[3qow]] – hKHMT + SAM <br /> | **[[3qow]] – hKHMT + SAM <br /> | ||
**[[4fmu]] – hKHMT SETD2 + inhibitor <br /> | **[[4fmu]] – hKHMT SETD2 + inhibitor <br /> | ||